PH12013500677A1 - 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators - Google Patents

4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators

Info

Publication number: PH12013500677A1
Authority: PH; Philippines
Prior art keywords: gpr; pyrazol; modulators; cyano; piperidine derivatives
Prior art date: 2010-11-23

Application number

PH1/2013/500677A

Other languages

English (en)

Inventor

Vincent Mascitti

Kim Francis Mcclure

Michael John Munchhof

Ralph Pelton Robinson Jr

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-11-23

Filing date

2011-11-09

Publication date

2013-05-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45418722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PH12013500677(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-11-09 Application filed by Pfizer filed Critical Pfizer

2013-05-06 Publication of PH12013500677A1 publication Critical patent/PH12013500677A1/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Diabetes (AREA)
Cardiology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Endocrinology (AREA)
Obesity (AREA)
Rheumatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Child & Adolescent Psychology (AREA)
Immunology (AREA)
Dermatology (AREA)
Gynecology & Obstetrics (AREA)
Vascular Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

PH1/2013/500677A 2010-11-23 2011-11-09 4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators PH12013500677A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41644110P	2010-11-23	2010-11-23
PCT/IB2011/054996 WO2012069948A1 (en)	2010-11-23	2011-11-09	4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators

Publications (1)

Publication Number	Publication Date
PH12013500677A1 true PH12013500677A1 (en)	2013-05-06

Family

ID=45418722

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH1/2013/500677A PH12013500677A1 (en)	2010-11-23	2011-11-09	4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators

Country Status (27)

Country	Link
EP (1)	EP2643310A1 (es)
JP (1)	JP2013543885A (es)
KR (1)	KR20130083915A (es)
CN (1)	CN103298801A (es)
AP (1)	AP2013006809A0 (es)
AR (1)	AR088121A1 (es)
AU (1)	AU2011333427A1 (es)
BR (1)	BR112013011865A2 (es)
CA (1)	CA2814231A1 (es)
CL (1)	CL2013001054A1 (es)
CO (1)	CO6801716A2 (es)
CR (1)	CR20130139A (es)
CU (1)	CU20130059A7 (es)
DO (1)	DOP2013000102A (es)
EA (1)	EA201370118A1 (es)
EC (1)	ECSP13012630A (es)
GT (1)	GT201300135A (es)
MA (1)	MA34805B1 (es)
MX (1)	MX2013004083A (es)
NI (1)	NI201300044A (es)
PE (1)	PE20140409A1 (es)
PH (1)	PH12013500677A1 (es)
SG (1)	SG189830A1 (es)
TW (1)	TWI433843B (es)
UY (1)	UY33742A (es)
WO (1)	WO2012069948A1 (es)
ZA (1)	ZA201302362B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2602813T3 (es)	2011-06-09	2017-02-22	Rhizen Pharmaceuticals S.A.	Nuevos compuestos como moduladores de GPR-119
CA2878625A1 (en)	2012-07-11	2014-01-16	Elcelyx Therapeutics, Inc.	Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2017119628A (ja) *	2014-05-09	2017-07-06	日産化学工業株式会社	置換アゾール化合物及び糖尿病治療薬
CN104592120A (zh) *	2015-02-13	2015-05-06	佛山市赛维斯医药科技有限公司	一种环丙基酰肼和甲氧苯类gpr119激动剂、制备方法及其用途
CN104610151A (zh) *	2015-02-13	2015-05-13	佛山市赛维斯医药科技有限公司	含酰肼和烷氧苯类结构的化合物、其制备方法及用途
CN104892517A (zh) *	2015-02-13	2015-09-09	佛山市赛维斯医药科技有限公司	酰肼类化合物、其制备方法及用途
CN108713016B (zh)	2016-02-18	2021-10-08	先正达参股股份有限公司	杀有害生物活性吡唑衍生物
CN106631992B (zh) *	2017-01-05	2019-01-18	桑迪亚医药技术（上海）有限责任公司	一种4-氧-3,4-二氢-2h-吡啶-1-甲酸叔丁酯的合成方法
CN115925702B (zh) *	2022-12-14	2025-04-25	江西凌富生物科技有限公司	一种咪唑并[4,5-c]吡啶衍生物的提纯方法及其咪唑并[4,5-c]吡啶衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR20100033419A (ko) *	2007-07-19	2010-03-29	메타볼렉스, 인코포레이티드	당뇨병 및 대사 장애의 치료를 위한 ｒｕｐ3 또는 ｇｐｒ119 수용체의 작용제로서 ｎ-아자시클릭 치환된 피롤, 피라졸, 이미다졸, 트리아졸 및 테트라졸 유도체
BRPI0909469A2 (pt) *	2008-03-31	2015-12-29	Metabolex Inc	compostos de oximetileno de arila e usos dos mesmos
JP2012528847A (ja) *	2009-06-05	2012-11-15	ファイザー・インク	Ｇｐｒ１１９調節因子としてのｌ−（ピペリジン−４−イル）−ピラゾール誘導体

2011
- 2011-11-09 CN CN2011800550665A patent/CN103298801A/zh active Pending
- 2011-11-09 PH PH1/2013/500677A patent/PH12013500677A1/en unknown
- 2011-11-09 SG SG2013023189A patent/SG189830A1/en unknown
- 2011-11-09 EA EA201370118A patent/EA201370118A1/ru unknown
- 2011-11-09 PE PE2013001058A patent/PE20140409A1/es not_active Application Discontinuation
- 2011-11-09 WO PCT/IB2011/054996 patent/WO2012069948A1/en not_active Ceased
- 2011-11-09 MX MX2013004083A patent/MX2013004083A/es unknown
- 2011-11-09 JP JP2013540458A patent/JP2013543885A/ja active Pending
- 2011-11-09 BR BR112013011865A patent/BR112013011865A2/pt not_active IP Right Cessation
- 2011-11-09 MA MA35928A patent/MA34805B1/fr unknown
- 2011-11-09 KR KR1020137013064A patent/KR20130083915A/ko not_active Ceased
- 2011-11-09 AU AU2011333427A patent/AU2011333427A1/en not_active Abandoned
- 2011-11-09 CA CA2814231A patent/CA2814231A1/en not_active Abandoned
- 2011-11-09 EP EP11802149.2A patent/EP2643310A1/en not_active Withdrawn
- 2011-11-09 AP AP2013006809A patent/AP2013006809A0/xx unknown
- 2011-11-21 UY UY0001033742A patent/UY33742A/es unknown
- 2011-11-22 AR ARP110104351A patent/AR088121A1/es not_active Application Discontinuation
- 2011-11-22 TW TW100142804A patent/TWI433843B/zh not_active IP Right Cessation
2013
- 2013-03-22 CR CR20130139A patent/CR20130139A/es unknown
- 2013-04-02 ZA ZA2013/02362A patent/ZA201302362B/en unknown
- 2013-04-16 CL CL2013001054A patent/CL2013001054A1/es unknown
- 2013-04-23 CU CU2013000059A patent/CU20130059A7/es unknown
- 2013-05-09 DO DO2013000102A patent/DOP2013000102A/es unknown
- 2013-05-13 NI NI201300044A patent/NI201300044A/es unknown
- 2013-05-20 EC ECSP13012630 patent/ECSP13012630A/es unknown
- 2013-05-21 GT GT201300135A patent/GT201300135A/es unknown
- 2013-05-23 CO CO13127143A patent/CO6801716A2/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
EA201370118A1 (ru)	2013-12-30
AP2013006809A0 (en)	2013-04-30
PE20140409A1 (es)	2014-03-23
ZA201302362B (en)	2014-06-25
UY33742A (es)	2012-06-29
CL2013001054A1 (es)	2013-09-27
TWI433843B (zh)	2014-04-11
KR20130083915A (ko)	2013-07-23
DOP2013000102A (es)	2013-07-15
EP2643310A1 (en)	2013-10-02
CO6801716A2 (es)	2013-11-29
MX2013004083A (es)	2013-06-13
WO2012069948A1 (en)	2012-05-31
CR20130139A (es)	2013-06-28
SG189830A1 (en)	2013-06-28
AU2011333427A1 (en)	2013-04-11
JP2013543885A (ja)	2013-12-09
CU20130059A7 (es)	2013-06-28
CA2814231A1 (en)	2012-05-31
ECSP13012630A (es)	2013-07-31
AR088121A1 (es)	2014-05-14
TW201300373A (zh)	2013-01-01
NI201300044A (es)	2013-08-01
MA34805B1 (fr)	2014-01-02
BR112013011865A2 (pt)	2016-08-23
CN103298801A (zh)	2013-09-11
GT201300135A (es)	2015-02-19

Publication	Publication Date	Title
MX2011013034A (es)	2012-02-08	1-(piperidin-4-yl)-pirazol derivados como moduladores de gpr 119.
PH12013500677A1 (en)	2013-05-06	4- (5-cyano-pyrazol-1-yl) -piperidine derivatives as gpr 119 modulators
WO2010106457A3 (en)	2010-11-18	3-oxa-7-azabicyclo[3.3.1]nonanes
MY153057A (en)	2014-12-31	Tryclic compounds,compositions and methods
MX392150B (es)	2025-03-21	Moduladores de receptores canabinoides.
NZ707778A (en)	2019-03-29	Therapeutic compounds and compositions and their use as pkm2 modulators
IN2012DN02679A (es)	2015-09-04
HN2010002774A (es)	2013-01-28	DERIVADOS DE 2-(1,5-DIHIDRO-5-OXO-1,2,4-TRIAZOL-4-IL/2-OXOIMIDAZOLIDIN-1-IL)PIRIDIN-4-CARBOXAMIDA ACTIVOS COMO MODULADORES DE ESTEAROIL-CoA
EA201270720A1 (ru)	2013-03-29	Модуляторы рецептора андрогенов и их применение
DK2459216T3 (da)	2013-12-09	Immunogene sammensætninger omfattende tlr-aktivitetsmodulatorer
NZ603151A (en)	2013-10-25	N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives
IN2013CN01340A (es)	2015-08-07
MX2012004078A (es)	2012-07-25	Compuestos y composiciones como moduladores de la actividad de gpr119.
MX2011011510A (es)	2011-11-18	Compuestos insecticidas de piridina.
MX2013002118A (es)	2013-04-03	2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
CY1116158T1 (el)	2017-02-08	Υποκατεστημενα 2-οξο- και 2-θειοξο-διυδροκινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
MX2013002295A (es)	2013-05-09	1-oxo-dihidroisoquinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3.
UA101110C2 (en)	2013-02-25	L-(piperidin-4-yl)-pyrazole derivatives as gpr119 modulators